Abbott Laboratories
(NYSE: ABT)

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. In August 2013, Abbott Laboratories completed its acquisition of OptiMedica Corporation. In August 2013, Abbott Laboratories completed its acquisition of IDEV Technologies.

111.200 -

-2.390 (-2.10%)
价格区间 111.430 - 113.760   (2.09%)
开盘 113.250
昨收 113.590
111.200
买盘 2
112.400
卖盘 10
成交量 11,538,190
成交额 655,920,213
注释 -
数据延迟。最后一次更新13 Feb 2026 06:19.
数据提供商
查看所有活动

关于 Abbott Laboratories

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. In August 2013, Abbott Laboratories completed its acquisition of OptiMedica Corporation. In August 2013, Abbott Laboratories completed its acquisition of IDEV Technologies.

Loading Chart...

Please login to view stock data and analysis